MitoMat · Decoding the role of mitochondrial dynamics in the mesenchymal-to-amoeboid transition and melanoma metastasis

Линиите свързват координатора с партньорите.

Накратко на български

Цел на проекта

Tumor cell migration and invasion represent the foundation of cancer metastasis. It is therefore critical to better understand themechanisms driving a specific subset of tumor cells to invade nearby tissues. Invasive cells are known to have an undifferentiated,mesenchymal-like state. However, under specific microenvironment conditions, mesenchymal cells become amoeboid, through aprocess known as the mesenchymal-to-amoeboid transition (MAT). Paradoxically, it is not the mesenchymal cells that are moremetastatic-prone, but the amoeboid cells. What is not yet fully understood is the precise cellular mechanisms driving MAT. Emergingevidence show that mitochondria are closely linked with cellular motility, especially in cancer. Mitochondrial dynamics, consistingmainly in mitochondrial fusion, fission, intracellular trafficking and turnover, was proven to be involved in the migration ofmesenchymal-like tumor cells. However, very little is known about the characteristics of lamellipodia-localized mitochondria in thesecancer cells on one hand, and how it might influence MAT and the amoeboid phenotype on the other. Therefore, I first aim toevaluate the role of mitochondrial dynamics in tumor microenvironment-triggered MAT during the 3D invasion of melanoma cells bycombining microfluidic and optogenetic approaches. Secondly, I will characterize the lamellipodia-localized mitochondria in terms ofproteome, age, energetic and oxidative status, in mesenchymal-like melanoma cells using biochemical, microfluidic and proteomicapproaches. By the end of the project, MitoMat would significantly improve the mechanistic understanding of how mitochondria arehijacked to fuel cancer cell motility, specifically within melanoma cells with different MAT phenotypes. If mitochondrial dynamicswould prove to be a driver for both cell invasion modalities (mesenchymal and amoeboid), our results could represent the premisesfor a future migrastatic therapy, targeting cancer metastasis.

Оригинален текст от CORDIS (на английски).

Участници

• INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE · ParisКоординаторФранция
• Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School · BostonСъединени щати

Връзки

• Виж в CORDIS
• DOI: 10.3030/101205724
• https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5286a1251&appId=PPGMS